INITIAL OBSERVATIONS OF ABLYNX'S PHASE II TTP PROGRAMME PRESENTED AT ISTH CONGRESS
GHENT, Belgium, 28 July 2011 - Ablynx [Euronext Brussels: ABLX] today announced
that initial observations of the on-going Phase II study with the anti-von
Willebrand factor (vWF) Nanobody ALX-0081/ALX-0681 in patients with thrombotic
thrombocytopenic purpura (TTP) were presented at the 13(th) Congress of the
International Society on Thrombosis and Haemostasis (ISTH) in Kyoto, Japan.
The presentation only includes initial findings and the data should not be
extrapolated for the overall study.
The data were presented by principal investigator, Dr. Flora Peyvandi (IRCCS
Maggiore Hospital Foundation, University of Milan), and included the study
design and goal, and the initial observations from the first five patients that
were enrolled in the trial. These were two men and three women, aged 31 to 60
years. Four patients experienced their first episode of TTP and one patient had
a history of recurrent TTP.
Three patients received Nanobody treatment, the other two received placebo
treatment. Four patients have completed the study treatment. Biological activity
of the Nanobody was confirmed by a decrease of the biomarker RICO compared with
placebo. Two serious adverse events occurred, but were resolved, with one
subject discontinuing treatment.
Recruitment of the Phase II study is currently ongoing and final data are
expected during the course of 2013 with a Marketing Authorisation Application
(MAA) filing in Europe planned end 2013, if the Phase II study is accepted as
pivotal.
For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:Â Â +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
    +32 (0)473 39 50 68
e:Â edwin.moses@ablynx.com
Marieke Vermeersch
Investor Relations Manager
t:Â Â +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:Â marieke.vermeersch@ablynx.com
Complete version of the press release:
http://hugin.info/137912/R/1533110/466968.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1533110]